Stem definition | Drug id | CAS RN |
---|---|---|
histamine-H2-receptor antagonists, cimetidine derivatives | 645 | 51481-61-9 |
Dose | Unit | Route |
---|---|---|
0.80 | g | O |
0.80 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 6.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 62 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 158.51 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 8.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.78 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 16, 1977 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urine abnormality | 148.19 | 13.68 | 58 | 14317 | 6641 | 56271051 |
Urine leukocyte esterase positive | 121.32 | 13.68 | 41 | 14334 | 3087 | 56274605 |
Body tinea | 116.26 | 13.68 | 33 | 14342 | 1387 | 56276305 |
Inhibitory drug interaction | 99.96 | 13.68 | 33 | 14342 | 2311 | 56275381 |
Infection susceptibility increased | 94.40 | 13.68 | 33 | 14342 | 2750 | 56274942 |
Lymphocyte count decreased | 88.09 | 13.68 | 66 | 14309 | 27873 | 56249819 |
Glucose tolerance impaired | 75.76 | 13.68 | 34 | 14341 | 5471 | 56272221 |
Culture urine positive | 72.61 | 13.68 | 29 | 14346 | 3499 | 56274193 |
Rheumatoid arthritis | 69.97 | 13.68 | 8 | 14367 | 382596 | 55895096 |
Urine ketone body present | 68.58 | 13.68 | 25 | 14350 | 2352 | 56275340 |
Blood urine present | 61.40 | 13.68 | 40 | 14335 | 13515 | 56264177 |
Purpura | 60.66 | 13.68 | 36 | 14339 | 10326 | 56267366 |
Hyperlipidaemia | 59.80 | 13.68 | 44 | 14331 | 18065 | 56259627 |
Impaired quality of life | 59.11 | 13.68 | 33 | 14342 | 8441 | 56269251 |
Chronic kidney disease | 57.53 | 13.68 | 62 | 14313 | 41994 | 56235698 |
Poor quality sleep | 56.08 | 13.68 | 42 | 14333 | 17713 | 56259979 |
Drug intolerance | 55.43 | 13.68 | 3 | 14372 | 264815 | 56012877 |
Bone density decreased | 51.39 | 13.68 | 35 | 14340 | 12725 | 56264967 |
Anaphylactoid reaction | 49.35 | 13.68 | 22 | 14353 | 3484 | 56274208 |
Erythema | 43.82 | 13.68 | 112 | 14263 | 155827 | 56121865 |
Joint swelling | 42.18 | 13.68 | 11 | 14364 | 289789 | 55987903 |
Neutrophil count increased | 41.99 | 13.68 | 33 | 14342 | 14932 | 56262760 |
Impaired work ability | 40.60 | 13.68 | 32 | 14343 | 14540 | 56263152 |
Torsade de pointes | 36.14 | 13.68 | 28 | 14347 | 12412 | 56265280 |
Oral herpes | 35.32 | 13.68 | 36 | 14339 | 22854 | 56254838 |
Band sensation | 33.51 | 13.68 | 11 | 14364 | 756 | 56276936 |
Drug ineffective | 33.31 | 13.68 | 122 | 14253 | 918867 | 55358825 |
Skin disorder | 32.88 | 13.68 | 37 | 14338 | 26272 | 56251420 |
Bacterial test positive | 31.02 | 13.68 | 18 | 14357 | 4950 | 56272742 |
Specific gravity urine decreased | 29.81 | 13.68 | 10 | 14365 | 735 | 56276957 |
Product use issue | 29.15 | 13.68 | 6 | 14369 | 186035 | 56091657 |
Tri-iodothyronine free decreased | 28.78 | 13.68 | 8 | 14367 | 311 | 56277381 |
Hypertension | 28.74 | 13.68 | 131 | 14244 | 244147 | 56033545 |
Creatinine urine decreased | 27.93 | 13.68 | 7 | 14368 | 181 | 56277511 |
Keratitis | 27.60 | 13.68 | 14 | 14361 | 2953 | 56274739 |
Infusion site scar | 27.25 | 13.68 | 8 | 14367 | 379 | 56277313 |
Red cell distribution width increased | 27.08 | 13.68 | 21 | 14354 | 9319 | 56268373 |
Urticaria | 26.29 | 13.68 | 89 | 14286 | 144587 | 56133105 |
Infusion site discomfort | 25.99 | 13.68 | 10 | 14365 | 1092 | 56276600 |
Circulatory collapse | 25.55 | 13.68 | 29 | 14346 | 20774 | 56256918 |
Therapeutic product effect decreased | 25.47 | 13.68 | 6 | 14369 | 169446 | 56108246 |
Cataract | 24.95 | 13.68 | 46 | 14329 | 51201 | 56226491 |
Arthropathy | 24.88 | 13.68 | 10 | 14365 | 200265 | 56077427 |
Cellulitis | 24.39 | 13.68 | 57 | 14318 | 74892 | 56202800 |
Product dose omission issue | 24.20 | 13.68 | 11 | 14364 | 204742 | 56072950 |
Anxiety | 23.76 | 13.68 | 105 | 14270 | 193067 | 56084625 |
Contraindicated product administered | 23.64 | 13.68 | 9 | 14366 | 186277 | 56091415 |
Electrocardiogram T wave amplitude decreased | 23.52 | 13.68 | 7 | 14368 | 348 | 56277344 |
Insomnia | 23.38 | 13.68 | 104 | 14271 | 191756 | 56085936 |
Wound | 22.75 | 13.68 | 4 | 14371 | 138800 | 56138892 |
Systemic lupus erythematosus | 22.35 | 13.68 | 9 | 14366 | 180069 | 56097623 |
Death | 22.11 | 13.68 | 156 | 14219 | 341270 | 55936422 |
Red blood cells urine positive | 21.95 | 13.68 | 12 | 14363 | 2944 | 56274748 |
Red blood cell count decreased | 21.91 | 13.68 | 36 | 14339 | 36581 | 56241111 |
Blood thyroid stimulating hormone increased | 21.78 | 13.68 | 16 | 14359 | 6547 | 56271145 |
Peripheral swelling | 21.58 | 13.68 | 17 | 14358 | 234709 | 56042983 |
Protein urine present | 21.51 | 13.68 | 15 | 14360 | 5661 | 56272031 |
Basophil count increased | 21.05 | 13.68 | 8 | 14367 | 845 | 56276847 |
Alanine aminotransferase increased | 21.02 | 13.68 | 62 | 14313 | 93600 | 56184092 |
White blood cell count decreased | 20.71 | 13.68 | 75 | 14300 | 125915 | 56151777 |
Urobilinogen urine increased | 20.24 | 13.68 | 6 | 14369 | 294 | 56277398 |
Nitrite urine present | 19.59 | 13.68 | 8 | 14367 | 1021 | 56276671 |
Infusion site rash | 19.29 | 13.68 | 9 | 14366 | 1583 | 56276109 |
Palmar-plantar erythrodysaesthesia syndrome | 18.80 | 13.68 | 25 | 14350 | 21040 | 56256652 |
Maternal exposure during pregnancy | 18.36 | 13.68 | 13 | 14362 | 189540 | 56088152 |
Flushing | 18.28 | 13.68 | 49 | 14326 | 70051 | 56207641 |
Chromaturia | 18.21 | 13.68 | 21 | 14354 | 15304 | 56262388 |
Food interaction | 18.19 | 13.68 | 7 | 14368 | 765 | 56276927 |
Myelosuppression | 17.59 | 13.68 | 22 | 14353 | 17433 | 56260259 |
Monocyte count decreased | 17.51 | 13.68 | 9 | 14366 | 1951 | 56275741 |
Pancreatitis acute | 16.81 | 13.68 | 26 | 14349 | 25098 | 56252594 |
Infusion site warmth | 16.70 | 13.68 | 8 | 14367 | 1492 | 56276200 |
White blood cells urine positive | 16.60 | 13.68 | 12 | 14363 | 4790 | 56272902 |
Thyroid cyst | 16.38 | 13.68 | 6 | 14369 | 572 | 56277120 |
Hepatic enzyme increased | 16.27 | 13.68 | 12 | 14363 | 171372 | 56106320 |
Feeling hot | 16.09 | 13.68 | 34 | 14341 | 41753 | 56235939 |
Intentional product use issue | 16.07 | 13.68 | 3 | 14372 | 99730 | 56177962 |
Red cell distribution width decreased | 16.02 | 13.68 | 8 | 14367 | 1631 | 56276061 |
Abdominal discomfort | 15.98 | 13.68 | 29 | 14346 | 277245 | 56000447 |
Blood creatinine decreased | 15.82 | 13.68 | 12 | 14363 | 5154 | 56272538 |
Lower respiratory tract infection | 15.49 | 13.68 | 5 | 14370 | 114789 | 56162903 |
Anion gap decreased | 15.40 | 13.68 | 5 | 14370 | 332 | 56277360 |
Glucose urine present | 15.27 | 13.68 | 6 | 14369 | 693 | 56276999 |
Arthralgia | 14.73 | 13.68 | 72 | 14303 | 501597 | 55776095 |
pH urine increased | 14.71 | 13.68 | 5 | 14370 | 383 | 56277309 |
Immune thrombocytopenia | 14.60 | 13.68 | 15 | 14360 | 9610 | 56268082 |
Eosinophil count increased | 14.58 | 13.68 | 15 | 14360 | 9622 | 56268070 |
Drug exposure before pregnancy | 14.37 | 13.68 | 6 | 14369 | 810 | 56276882 |
Herpes zoster | 14.05 | 13.68 | 47 | 14328 | 75842 | 56201850 |
Haematocrit increased | 13.97 | 13.68 | 8 | 14367 | 2146 | 56275546 |
Platelet count decreased | 13.96 | 13.68 | 59 | 14316 | 106324 | 56171368 |
Lactic acidosis | 13.89 | 13.68 | 29 | 14346 | 35317 | 56242375 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Chronic kidney disease | 35.61 | 15.68 | 39 | 5707 | 37936 | 31653662 |
Renal injury | 21.91 | 15.68 | 17 | 5729 | 10648 | 31680950 |
Mucosal erosion | 20.14 | 15.68 | 7 | 5739 | 810 | 31690788 |
Palmar-plantar erythrodysaesthesia syndrome | 18.28 | 15.68 | 18 | 5728 | 15465 | 31676133 |
Peptic ulcer | 18.10 | 15.68 | 9 | 5737 | 2567 | 31689031 |
Decreased appetite | 16.48 | 15.68 | 63 | 5683 | 153154 | 31538444 |
Adulterated product | 16.15 | 15.68 | 3 | 5743 | 25 | 31691573 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urine abnormality | 157.14 | 13.23 | 62 | 16836 | 7776 | 70903770 |
Urine leukocyte esterase positive | 117.96 | 13.23 | 41 | 16857 | 3604 | 70907942 |
Body tinea | 114.79 | 13.23 | 32 | 16866 | 1351 | 70910195 |
Lymphocyte count decreased | 93.94 | 13.23 | 80 | 16818 | 43459 | 70868087 |
Infection susceptibility increased | 90.85 | 13.23 | 32 | 16866 | 2925 | 70908621 |
Inhibitory drug interaction | 90.16 | 13.23 | 34 | 16864 | 3773 | 70907773 |
Urine ketone body present | 75.77 | 13.23 | 29 | 16869 | 3350 | 70908196 |
Culture urine positive | 69.41 | 13.23 | 29 | 16869 | 4208 | 70907338 |
Glucose tolerance impaired | 68.09 | 13.23 | 33 | 16865 | 6773 | 70904773 |
Impaired quality of life | 56.95 | 13.23 | 32 | 16866 | 8884 | 70902662 |
Poor quality sleep | 55.75 | 13.23 | 43 | 16855 | 20306 | 70891240 |
Bone density decreased | 54.47 | 13.23 | 34 | 16864 | 11440 | 70900106 |
Hyperlipidaemia | 53.83 | 13.23 | 45 | 16853 | 23818 | 70887728 |
Blood urine present | 51.07 | 13.23 | 40 | 16858 | 19313 | 70892233 |
Purpura | 49.27 | 13.23 | 38 | 16860 | 17937 | 70893609 |
Erythema | 44.53 | 13.23 | 126 | 16772 | 199437 | 70712109 |
Anaphylactoid reaction | 43.33 | 13.23 | 22 | 16876 | 4985 | 70906561 |
Rheumatoid arthritis | 40.24 | 13.23 | 10 | 16888 | 291795 | 70619751 |
Hypertension | 37.79 | 13.23 | 155 | 16743 | 295878 | 70615668 |
Torsade de pointes | 36.45 | 13.23 | 32 | 16866 | 18084 | 70893462 |
Impaired work ability | 35.18 | 13.23 | 30 | 16868 | 16310 | 70895236 |
Oral herpes | 33.93 | 13.23 | 35 | 16863 | 24151 | 70887395 |
Red cell distribution width increased | 33.40 | 13.23 | 27 | 16871 | 13630 | 70897916 |
Urticaria | 32.57 | 13.23 | 99 | 16799 | 162950 | 70748596 |
Off label use | 32.19 | 13.23 | 82 | 16816 | 742978 | 70168568 |
Band sensation | 30.94 | 13.23 | 10 | 16888 | 702 | 70910844 |
Palmar-plantar erythrodysaesthesia syndrome | 30.76 | 13.23 | 37 | 16861 | 30210 | 70881336 |
Joint swelling | 30.68 | 13.23 | 11 | 16887 | 253200 | 70658346 |
Infusion site scar | 29.69 | 13.23 | 8 | 16890 | 297 | 70911249 |
Specific gravity urine decreased | 29.31 | 13.23 | 10 | 16888 | 831 | 70910715 |
Flushing | 29.10 | 13.23 | 62 | 16836 | 82110 | 70829436 |
Skin disorder | 29.04 | 13.23 | 36 | 16862 | 30321 | 70881225 |
Alanine aminotransferase increased | 28.94 | 13.23 | 89 | 16809 | 147391 | 70764155 |
Chronic kidney disease | 28.83 | 13.23 | 52 | 16846 | 61005 | 70850541 |
Keratitis | 28.19 | 13.23 | 15 | 16883 | 3742 | 70907804 |
Tri-iodothyronine free decreased | 28.09 | 13.23 | 8 | 16890 | 365 | 70911181 |
Red blood cell count decreased | 27.99 | 13.23 | 47 | 16851 | 52114 | 70859432 |
Infusion site discomfort | 27.74 | 13.23 | 10 | 16888 | 977 | 70910569 |
Bacterial test positive | 26.42 | 13.23 | 18 | 16880 | 7013 | 70904533 |
Haematocrit increased | 25.66 | 13.23 | 14 | 16884 | 3668 | 70907878 |
Monocyte count decreased | 25.27 | 13.23 | 13 | 16885 | 3026 | 70908520 |
Insomnia | 24.64 | 13.23 | 110 | 16788 | 217696 | 70693850 |
Drug ineffective | 24.04 | 13.23 | 129 | 16769 | 939623 | 69971923 |
Cataract | 23.28 | 13.23 | 45 | 16853 | 55600 | 70855946 |
Neutrophil count increased | 22.82 | 13.23 | 30 | 16868 | 26765 | 70884781 |
White blood cell count decreased | 22.40 | 13.23 | 90 | 16808 | 170051 | 70741495 |
Peptic ulcer | 22.36 | 13.23 | 15 | 16883 | 5698 | 70905848 |
Gastrooesophageal reflux disease | 21.86 | 13.23 | 59 | 16839 | 90780 | 70820766 |
Creatinine urine decreased | 21.81 | 13.23 | 6 | 16892 | 241 | 70911305 |
Therapeutic product effect decreased | 21.53 | 13.23 | 4 | 16894 | 143014 | 70768532 |
Infusion site rash | 21.43 | 13.23 | 9 | 16889 | 1323 | 70910223 |
Basophil count increased | 21.16 | 13.23 | 9 | 16889 | 1364 | 70910182 |
Ventricular tachycardia | 21.13 | 13.23 | 34 | 16864 | 36389 | 70875157 |
Secondary adrenocortical insufficiency | 21.08 | 13.23 | 11 | 16887 | 2636 | 70908910 |
Mean cell haemoglobin increased | 20.61 | 13.23 | 12 | 16886 | 3561 | 70907985 |
Red cell distribution width decreased | 19.68 | 13.23 | 9 | 16889 | 1620 | 70909926 |
Protein urine present | 19.64 | 13.23 | 17 | 16881 | 9423 | 70902123 |
Dyspepsia | 19.60 | 13.23 | 56 | 16842 | 89021 | 70822525 |
Contusion | 19.54 | 13.23 | 71 | 16827 | 127965 | 70783581 |
Blood thyroid stimulating hormone increased | 19.14 | 13.23 | 16 | 16882 | 8463 | 70903083 |
Infusion site warmth | 19.13 | 13.23 | 8 | 16890 | 1163 | 70910383 |
Nitrite urine present | 19.12 | 13.23 | 8 | 16890 | 1164 | 70910382 |
Therapeutic product effect incomplete | 18.82 | 13.23 | 3 | 16895 | 119879 | 70791667 |
Peripheral swelling | 17.86 | 13.23 | 18 | 16880 | 236545 | 70675001 |
White blood cells urine positive | 17.85 | 13.23 | 13 | 16885 | 5627 | 70905919 |
Drug exposure before pregnancy | 17.40 | 13.23 | 6 | 16892 | 515 | 70911031 |
Product dose omission issue | 17.05 | 13.23 | 16 | 16882 | 217452 | 70694094 |
Anxiety | 17.01 | 13.23 | 100 | 16798 | 220230 | 70691316 |
Aspartate aminotransferase increased | 16.57 | 13.23 | 67 | 16831 | 126911 | 70784635 |
Leukocyturia | 16.56 | 13.23 | 8 | 16890 | 1629 | 70909917 |
Electrocardiogram T wave amplitude decreased | 16.51 | 13.23 | 6 | 16892 | 600 | 70910946 |
Infusion site pruritus | 16.40 | 13.23 | 10 | 16888 | 3227 | 70908319 |
Eosinophil count increased | 16.10 | 13.23 | 19 | 16879 | 15203 | 70896343 |
Urobilinogen urine increased | 15.87 | 13.23 | 6 | 16892 | 670 | 70910876 |
Platelet count decreased | 15.82 | 13.23 | 84 | 16814 | 178138 | 70733408 |
Arthropathy | 15.80 | 13.23 | 8 | 16890 | 150049 | 70761497 |
Product use issue | 15.62 | 13.23 | 12 | 16886 | 179925 | 70731621 |
Red blood cells urine positive | 15.24 | 13.23 | 11 | 16887 | 4698 | 70906848 |
Circulatory collapse | 15.22 | 13.23 | 29 | 16869 | 35445 | 70876101 |
Blood alkaline phosphatase increased | 15.08 | 13.23 | 39 | 16859 | 58482 | 70853064 |
Thyroid cyst | 14.93 | 13.23 | 5 | 16893 | 392 | 70911154 |
Blood creatinine decreased | 14.82 | 13.23 | 13 | 16885 | 7336 | 70904210 |
Mean cell haemoglobin concentration increased | 14.76 | 13.23 | 6 | 16892 | 812 | 70910734 |
Mucosal erosion | 14.72 | 13.23 | 8 | 16890 | 2081 | 70909465 |
pH urine increased | 14.48 | 13.23 | 5 | 16893 | 431 | 70911115 |
Contraindicated product administered | 14.44 | 13.23 | 7 | 16891 | 134605 | 70776941 |
Cellulitis | 14.37 | 13.23 | 54 | 16844 | 98874 | 70812672 |
Wound | 14.36 | 13.23 | 3 | 16895 | 98729 | 70812817 |
Gamma-glutamyltransferase increased | 14.34 | 13.23 | 35 | 16863 | 50650 | 70860896 |
Product use in unapproved indication | 14.32 | 13.23 | 17 | 16881 | 207461 | 70704085 |
Blood lactate dehydrogenase increased | 14.20 | 13.23 | 28 | 16870 | 35099 | 70876447 |
Food interaction | 13.78 | 13.23 | 7 | 16891 | 1586 | 70909960 |
Duodenal ulcer haemorrhage | 13.78 | 13.23 | 12 | 16886 | 6706 | 70904840 |
Coronary artery disease | 13.37 | 13.23 | 39 | 16859 | 62697 | 70848849 |
Hepatic function abnormal | 13.29 | 13.23 | 41 | 16857 | 67955 | 70843591 |
None
Source | Code | Description |
---|---|---|
ATC | A02BA01 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
ATC | A02BA51 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
CHEBI has role | CHEBI:37961 | H2 receptor antagonists |
CHEBI has role | CHEBI:49201 | anti-ulcer drugs |
CHEBI has role | CHEBI:50183 | P450 inhibitors |
CHEBI has role | CHEBI:60809 | adjuvants |
MeSH PA | D000897 | Anti-Ulcer Agents |
MeSH PA | D065609 | Cytochrome P-450 CYP1A2 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006635 | Histamine H2 Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D018377 | Neurotransmitter Agents |
FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Heartburn | indication | 16331000 | |
Upper gastrointestinal hemorrhage | indication | 37372002 | |
Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
Multiple endocrine adenomas | indication | 60549007 | |
Indigestion | indication | 162031009 | |
Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
Systemic mast cell disease | indication | 397016004 | DOID:349 |
Gastric ulcer | indication | 397825006 | DOID:10808 |
Upper GI Bleed Prevention | indication | ||
Maintenance of Healing Duodenal Ulcer | indication | ||
Pancreatic insufficiency | off-label use | 37992001 | |
Urticaria | off-label use | 126485001 | |
Prevention of Stress Ulcer | off-label use | ||
NSAID-Induced Gastric Ulcer | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.83 | acidic |
pKa2 | 6.71 | Basic |
pKa3 | 0.0 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 6.14 | WOMBAT-PK | CHEMBL | |||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.16 | PDSP | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.92 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | INHIBITOR | Ki | 5.10 | IUPHAR | ||||
Histamine H2 receptor | GPCR | Kd | 6.58 | CHEMBL | |||||
Histamine H2 receptor | GPCR | ANTAGONIST | Ki | 5.90 | IUPHAR |
ID | Source |
---|---|
4018845 | VUID |
N0000147147 | NUI |
D00295 | KEGG_DRUG |
70059-30-2 | SECONDARY_CAS_RN |
152402 | RXNORM |
4018844 | VANDF |
4018845 | VANDF |
C0008783 | UMLSCUI |
CHEBI:3699 | CHEBI |
CHEMBL30 | ChEMBL_ID |
CHEMBL1201051 | ChEMBL_ID |
DB00501 | DRUGBANK_ID |
D002927 | MESH_DESCRIPTOR_UI |
2756 | PUBCHEM_CID |
1231 | IUPHAR_LIGAND_ID |
3765 | INN_ID |
80061L1WGD | UNII |
101 | MMSL |
2261 | MMSL |
4448 | MMSL |
4449 | MMSL |
6098 | MMSL |
d00140 | MMSL |
003415 | NDDF |
004987 | NDDF |
373541007 | SNOMEDCT_US |
83051006 | SNOMEDCT_US |
83532008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8192 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8192 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8204 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8204 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8305 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8305 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
Good Sense Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 0113-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0649 | SOLUTION | 300 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0649 | SOLUTION | 300 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1298 | SOLUTION | 400 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1298 | SOLUTION | 400 mg | ORAL | ANDA | 15 sections |
cimetidineacid reducer | HUMAN OTC DRUG LABEL | 1 | 0363-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0053 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0317 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0372 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0541 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1282 | TABLET | 400 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-626 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-627 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-048 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 17 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-265 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-372 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-531 | TABLET | 300 mg | ORAL | ANDA | 14 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-532 | TABLET | 400 mg | ORAL | ANDA | 14 sections |
Good Neighbor Pharmacy Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 24385-111 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 30142-323 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-024 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-217 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-218 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Equate Cimetidine | HUMAN OTC DRUG LABEL | 1 | 49035-820 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |